| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Outline of Final Research Achievements |
Inflammatory monocytes play a key role in atherosclerotic plaque destabilization and rupture. We hypothesized that regulating inflammatory monocytes enable to prevent atherosclerotic plaque destabilization and rupture. We developed nanoparticle-mediated drug delivery system (Nano-DDS) using polylactide-co-glycolic acid (PLGA)-based nanoparticle targeting inflammatory monocytes (Ly-6Chigh monocytes) for the treatment of plaque destabilization and rupture. In ApoE-KO mice, nanoparticle-mediated monocyte-selective delivery of HMG-CoA reductase inhibitor, pitavastatin, inhibited the release of inflammatory monocytes to peripheral blood, and reduced the incidence of plaque ruptures in the brachiocephalic arteries. These results suggested that this new therapeutics might prevent plaque destabilization and rupture by regulating inflammatory monocytes.
|
